Chandrakanth Amaram, MD
General Practice · Waycross, GANPI 1992730881
Payments from drug & device makers
Across 17 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$132
- AstraZeneca$70
- Novo Nordisk$47
- Kyowa Kirin, Inc.$25
- Johnson & Johnson$22
- Sunovion Pharmaceuticals Inc.$19
- plus $47 from 3 others
What the payments were for
- Food & beverage$361100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 3 | $132 |
| AstraZeneca | 5 | $70 |
| Novo Nordisk | 3 | $47 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$361 in reported general payments places this provider in the 55th percentile of 2,542 general practice providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 30 | $48,293 |
| LinzessLinaclotide | 23 | $24,961 |
| EliquisApixaban | 18 | $12,905 |
| MyrbetriqMirabegron | 15 | $11,404 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,276 |
| Sevelamer Carbonate | 20 | $5,348 |
| ProsolParenteral Amino Acid 20% No.1 | 38 | $4,219 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 33 | $2,334 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 13 | $2,089 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 110 | $1,959 |
| Amlodipine Besylate | 216 | $1,074 |
| Gabapentin | 38 | $1,038 |
| Atorvastatin Calcium | 136 | $1,025 |
| Comfort Ez Insulin SyringeSyringe-Needle,insulin,0.5 Ml | 11 | $971 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $954 |
Paid to pharmacies, not to this prescriber.
Other general practice in Waycross
- Warren TheisWaycross$30K
- Edward SchlisselMarietta$665K
- Peter VanstromTucker$424K
- Robert PauleyUnion City$155K
- Hoyt GazawayBuford$145K
- Stanton McKennaAtlanta$75K
- Carlos TanGainesville$75K
- Michael BoydAugusta$67K
- Michael KatzAtlanta$66K
- Harris SiegelAtlanta$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.